# Breatheasy Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/breatheasy

- Industry: Biotechnology
- Headquarters: Alameda, US
- Website: www.mymiist.com/
- Total disclosed funding: $7M
- Latest round: Seed (Feb 5, 2025)
- Investors on record: 5

## About

Based in California, US, and founded in 2019 by founders Dalton Signor and Miist Therapeutics, doing business as Breatheasy Co. Miist Therapeutics offers inhalable medications designed to help individuals quit smoking by providing instant-acting therapies. In August 2024, Breatheasy Co. raised USD 6.3 million in venture funding.


Breatheasy's core products are its inhalation drug delivery systems. These systems are designed to allow patients to self-administer medication in a controlled dose through the respiratory system. The company has developed several types of inhalers, including dry powder inhalers (DPIs), metered dose inhalers (MDIs), and nebulizers, each suited for different patient needs and drug types.

## Funding rounds

- Seed, Feb 5, 2025, $7M — Entrepreneur First, 1517 Fund, Refactor Capital, Freeflow Ventures, California Innovation Fund

## Investors

- Entrepreneur First (https://capitalatlas.ai/funds/entrepreneur-first) — Seed
- 1517 Fund (https://capitalatlas.ai/funds/1517-fund) — Seed
- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed
- Freeflow Ventures (https://capitalatlas.ai/funds/freeflow-ventures) — Seed
- California Innovation Fund (https://capitalatlas.ai/funds/california-innovation-fund) — Seed